Condition: SLE (Systemic Lupus) · Systemic Sclerosis · ANCA Associated Vasculitis · Sponsor: Nanjing Bioheng Biotech Co., Ltd.
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CD19 or CD19-BCMA CAR-T in patients with active SLE, SSc, AAV, IIM and pSS.
This description comes directly from the study's public registry record.
Peng Yu · 18451117657 · peng.yu@bioheng.com
Ming Gao · 17714188689 · ming.gao@bioheng.com
Always discuss trial participation with your own doctor first.
| The Third the People's Hospital of Bengbu | Bengbu, Anhui, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06548607